28 January 2016  
EMA/CHMP/37179/2016  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Revlimid 
lenalidomide 
On 28 January2016, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Revlimid. The marketing authorisation holder for this medicinal product is Celgene Europe Limited. 
The CHMP adopted a new indication as follows: 
"Revlimid is indicated for the treatment of adult patients with relapsed or refractory mantle cell 
lymphoma (see sections 4.4 and 5.1)." 
For information, the full indications for Revlimid will be as follows2: 
"Multiple myeloma 
Revlimid is indicated for the treatment of adult patients with previously untreated multiple myeloma 
who are not eligible for transplant (see section 4.2). 
Revlimid in combination with dexamethasone is indicated for the treatment of multiple myeloma in 
adult patients who have received at least one prior therapy. 
Myelodysplastic syndromes 
Revlimid is indicated for the treatment of patients with transfusion-dependent anaemia due to low- 
or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q 
cytogenetic abnormality when other therapeutic options are insufficient or inadequate. 
Mantle cell lymphoma 
Revlimid is indicated for the treatment of adult patients with relapsed or refractory 
mantle cell lymphoma (see sections 4.4 and 5.1)." 
Detailed recommendations for the use of this product will be described in the updated summary of product 
characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), 
and will be available in all official European Union languages after a decision on this change to the marketing 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days 
from adoption of the opinion 
2 New text in bold 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
                                                
authorisation has been granted by the European Commission. 
Revlimid  
EMA/CHMP/37179/2016 
Page 2/2 
 
  
  
